Eli Lilly has formally submitted its investigational oral GLP-1 receptor agonist, orforglipron, to the U.S. Food and Drug Administration, aiming for approval in early 2026. Unlike existing weekly injectables, orforglipron is administered as a once-daily capsule, offering patients greater convenience and potentially lower manufacturing and distribution costs. The company received a Commissioner’s National Priority Review Voucher, shortening the expected review timeline to approximately two months, compared with the standard 10–12 months for novel therapies.

In a pivotal phase 3 study presented this month, Lilly’s dual agonist retatrutide delivered an average weight loss of 28.7% at the highest dose over 48 weeks, surpassing results of many competitors. The trial enrolled over 500 participants with obesity, showing consistent reductions in body mass index and waist circumference, as well as favorable safety and tolerability profiles. These data position retatrutide as a potential best-in-class therapy if approved, reinforcing Lilly’s leadership in next-generation metabolic medicines.

To support anticipated global demand for its diabetes and obesity portfolio, Eli Lilly announced a capital investment exceeding $1 billion to develop a manufacturing network in India. The program will partner with local contract development and manufacturing organizations to produce complex injectables and vials, enhancing supply resilience and potentially reducing cash-pay costs in emerging markets. Operations are slated to begin in mid-2026, with initial capacity targeting annual production of more than 10 million pen doses.